Dafinchi AI

HOLX

Healthcare

2w

Progress in Breast Health Business and New Product Launches

Management highlighted sequential revenue growth and early signs of recovery in Breast Health, with a focus on interventional sales increasing 31.8%.
The upcoming launch of the Envision system in 2026 is expected to be a significant growth driver, with the current focus on replacing older gantries and expanding the interventional segment.

Laboratory Corporation of America Holdings

LH

Healthcare

3w

Impact and Management of PAMA Legislation for 2026

The company anticipates a potential $100 million impact if PAMA is implemented next year, with ongoing efforts to delay or mitigate this through legislation and data collection improvements.
Management is working with trade organizations to seek legislative solutions, including delays and data adjustments, to offset the impact.
Base case assumption is that PAMA will come into effect in 2026, but the company is preparing for various scenarios, including offsets via initiatives like LaunchPad.

DXCM

Healthcare

2w

Expansion of Type 2 Non-Insulin Coverage and Market Penetration

Coverage for nearly 6 million type 2 non-insulin lives established with three major PBMs in the U.S.
Work ongoing to build coverage for the entire 25 million U.S. type 2 population.
Strong growth from type 2 non-insulin population driven by new coverage and clinical recognition of CGM benefits.
Continued momentum with new access wins, personalized software, and product portfolio leverage.

ADMA Biologics, Inc.

ADMA

Healthcare

1w

Gross Margin Expansion and Cost Management

Gross margins improved to 55.1% in Q2 2025, driven by higher-margin IG sales and manufacturing efficiencies from yield enhancement.
Management sees no current headwinds to margin growth and expects continued accretion as growth accelerates.
The company is actively managing plasma supply costs and rebates, with no significant obstacles to margin improvement in the near term.

Oscar Health, Inc.

OSCR

Healthcare

1w

Long-term Earnings Levers and Strategic Flexibility

Oscar continues to accelerate cost reductions, including AI-driven efficiencies and operational improvements, to enhance long-term profitability.
Management emphasized ongoing opportunities in fraud, waste, and abuse reduction, provider contract renegotiations, and ICHRA expansion.
The company is actively pulling all available levers to set up 2026 and beyond as profitable years, with a focus on long-term growth.
There is an acknowledgment that some opportunities could be pulled forward if market conditions necessitate, to accelerate earnings growth.

Alignment Healthcare, Inc.

ALHC

Healthcare

2w

Rapid Membership Growth Outpacing Industry with 28% YoY Increase

Membership reached 223,700 members, a 28% increase YoY, supporting a 49% revenue growth to $1 billion in Q2 2025.
Strong growth validates the business model and confidence in 2026 bids, with capacity to expand into new counties and states.
Management emphasizes the durability of their model amid evolving Medicare landscape, including V28 risk model changes.

Boston Scientific Corporation

BSX

Healthcare

3w

Exceptional Second Quarter Growth and Outperformance

Total company operational sales grew 22%, organic sales grew 17%, exceeding guidance of 13-15%.
Second quarter adjusted EPS of $0.75 increased 23%, surpassing guidance of $0.71-$0.73.
Strong momentum driven by Cardiovascular segment, especially in the U.S. and Asia Pacific.

Intuitive Surgical, Inc.

ISRG

Healthcare

3w

Launch and Adoption of da Vinci 5 Platform in Key Markets

Broad launch of da Vinci 5 in the U.S. with over 100,000 procedures performed to date.
Received clearances in Europe and Japan, with measured launches planned.
Focus on building infrastructure, training, and customer engagement for regional rollouts.
Early adopters in Europe and Japan expected to respond to new technology, with some customers waiting for specific features like force feedback.

Integra LifeSciences Holdings Corporation

IART

Healthcare

2w

Progress on Compliance Master Plan and Quality System Transformation

All internal manufacturing sites assessed ahead of Q3 timeline with no related shipholds identified or initiated since last call.
Remediation planning and execution underway, with efforts aligned to FDA Quality System Regulations.
Some remediation work extending into 2026, with continuous improvement becoming standard in highly regulated industry.
Positive outcomes from FDA inspections at two facilities not covered by warning letters.
Ongoing updates and actions related to FDA warning letters, supporting operational strength and supply chain reliability.

HealthStream, Inc.

HSTM

Healthcare

1w

Record Quarterly Revenue Achieved with 4% Growth

HealthStream achieved record quarterly revenue of $74.4 million, up 4% from Q2 2024.
Growth driven by strong subscription revenue, offset by declines in legacy products.
Revenue from core subscription products increased by 4.2%.
The company expects continued growth in subscription revenue and declining legacy product impact.

OraSure Technologies, Inc.

OSUR

Healthcare

1w

Progress on Strategic Pillars and Innovation Roadmap

OTI is advancing its strategic transformation focusing on strengthening foundation, elevating core growth, and accelerating profitable growth.
Reported revenue in Q2 was in the top half of guidance range.
Launched HEMAcollect PROTEIN in July to expand into proteomic research and blood sample management.
Progress on innovation includes new product launches and expanding client relationships.
Management emphasizes disciplined execution and long-term value creation.